Company profile for Moleculin Biotech

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are highly focused on developing treatments for highly resistant cancers. Our Goal: Reinventing a Cornerstone of Cancer Treatment with the Intent to Provide Safer and More Effective Chemotherapy. We have three core technologies, all of which are based on discoveries made at M.D. Anderson Cancer Center by Dr. Waldemar Priebe and his team. Our clinical stage drugs are Annamycin, a Next Generation Anthracycline being studied f...
We are highly focused on developing treatments for highly resistant cancers. Our Goal: Reinventing a Cornerstone of Cancer Treatment with the Intent to Provide Safer and More Effective Chemotherapy. We have three core technologies, all of which are based on discoveries made at M.D. Anderson Cancer Center by Dr. Waldemar Priebe and his team. Our clinical stage drugs are Annamycin, a Next Generation Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML, and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer and AML.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
5300 Memorial Drive, Suite 950 Houston, TX, 77007
Telephone
Telephone
(713) 300-5160
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Moleculin Announces Reverse Stock Split
Moleculin Announces Reverse Stock Split

26 Nov 2025

// GLOBENEWSWIRE

https://www.globenewswire.com/news-release/2025/11/26/3195167/0/en/Moleculin-Announces-Reverse-Stock-Split.html

GLOBENEWSWIRE
26 Nov 2025

https://www.globenewswire.com/news-release/2025/11/26/3195185/0/en/Moleculin-to-Participate-in-the-Virtual-Investor-Closing-Bell-Series.html

GLOBENEWSWIRE
26 Nov 2025

https://www.globenewswire.com/news-release/2025/11/13/3187380/0/en/Moleculin-Reports-60-of-First-45-Subjects-in-Pivotal-MIRACLE-Phase-3-AML-Trial-Consented.html

GLOBENEWSWIRE
13 Nov 2025

https://www.globenewswire.com/news-release/2025/11/12/3186289/0/en/Moleculin-Announces-Grant-Funded-Research-Evaluating-Annamycin-for-the-Treatment-of-Pancreatic-Cancer-at-UNC-Chapel-Hill.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/10/30/3177430/0/en/Moleculin-to-Highlight-its-Ongoing-Phase-3-Acute-Myeloid-Leukemia-MIRACLE-Clinical-Trial-at-the-14th-Annual-Acute-Leukemia-Meeting.html

GLOBENEWSWIRE
30 Oct 2025

https://www.globenewswire.com/news-release/2025/10/29/3176459/0/en/Moleculin-Expands-Global-IP-Portfolio-with-New-Australian-Patent-for-Annamycin.html

GLOBENEWSWIRE
29 Oct 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty